GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
Ticker SymbolGSK
Company nameGSK plc
IPO dateMay 22, 1972
CEOWaterhouse (Deborah)
Number of employees68629
Security typeDepository Receipt
Fiscal year-endMay 22
Address980 Great West Road
CityBRENTFORD
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited Kingdom
Postal codeTW8 9GS
Phone442080475000
Websitehttps://www.gsk.com/
Ticker SymbolGSK
IPO dateMay 22, 1972
CEOWaterhouse (Deborah)